Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Sureda

Showing results (141-150 of 380) with videos related to

Pageof 38
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Introduction of a quality management system and outcome after hematopoietic stem-cell transplantationAlois Gratwohl, Ronald Brand, Dietger Niederwieser, et al.
Frontiers in Immunology|March 8, 2024
CD200 genotype is associated with clinical outcome of patients with multiple myelomaYolanda Gonzalez-Montes, Gemma Osca-Gelis, Rocío Rodriguez-Romanos, et al.
Blood Advances|June 5, 2025
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphomaAlexey V Danilov, Swetha Kambhampati Thiruvengadam, Kim Linton, et al.
Journal of Hematology & Oncology|June 14, 2017
Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphomaNarendranath Epperla, Kwang Woo Ahn, Sairah Ahmed, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 19, 2011
High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation RegistryNicolas Mounier, Carmen Canals, Christian Gisselbrecht, et al.
Hematological Oncology|February 4, 2017
Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcomeMarc Sorigue, Santiago Mercadal, Sara Alonso, et al.
Bone Marrow Transplantation|March 6, 2023
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity SurveyJakob R Passweg, Helen Baldomero, Fabio Ciceri, et al.
Bone Marrow Transplantation|March 4, 2024
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMTJakob R Passweg, Helen Baldomero, Fabio Ciceri, et al.
Leukemia & Lymphoma|July 14, 2020
Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMTCarmen Martínez, Ariane Boumendil, Joanna Romejko-Jarosinska, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|November 23, 2019
Clinicopathologic features and prognostic significance of CD30 expression in <i>de novo</i> diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institutionMaría Queralt Salas, Fina Climent, Gustavo Tapia, et al.
Pageof 38

Showing results (141-150 of 380) with videos related to

Sort By:
Pageof 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Introduction of a quality management system and outcome after hematopoietic stem-cell transplantationAlois Gratwohl, Ronald Brand, Dietger Niederwieser, et al.
Frontiers in Immunology|March 8, 2024
CD200 genotype is associated with clinical outcome of patients with multiple myelomaYolanda Gonzalez-Montes, Gemma Osca-Gelis, Rocío Rodriguez-Romanos, et al.
Blood Advances|June 5, 2025
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphomaAlexey V Danilov, Swetha Kambhampati Thiruvengadam, Kim Linton, et al.
Journal of Hematology & Oncology|June 14, 2017
Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphomaNarendranath Epperla, Kwang Woo Ahn, Sairah Ahmed, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 19, 2011
High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation RegistryNicolas Mounier, Carmen Canals, Christian Gisselbrecht, et al.
Hematological Oncology|February 4, 2017
Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcomeMarc Sorigue, Santiago Mercadal, Sara Alonso, et al.
Bone Marrow Transplantation|March 6, 2023
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity SurveyJakob R Passweg, Helen Baldomero, Fabio Ciceri, et al.
Bone Marrow Transplantation|March 4, 2024
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMTJakob R Passweg, Helen Baldomero, Fabio Ciceri, et al.
Leukemia & Lymphoma|July 14, 2020
Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMTCarmen Martínez, Ariane Boumendil, Joanna Romejko-Jarosinska, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|November 23, 2019
Clinicopathologic features and prognostic significance of CD30 expression in <i>de novo</i> diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institutionMaría Queralt Salas, Fina Climent, Gustavo Tapia, et al.
Pageof 38